Drugs / Glucopyranosyl Lipid A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03463135 | May 2018 → May 2019 | food allergy | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01864876 | Sep 2012 → Dec 2013 | — | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01147068 | Jun 2010 → Oct 2011 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03742804 | Jun → Dec 2019 | primary cutaneous T-cell lymphoma | Yale University | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01154049 Background | Mar 2011 → Apr 2014 | schistosomiasis | Oswaldo Cruz Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glucopyranosyl lipid A | “The vaccine was formulated with glucopyranosyl lipid A (GLA) adjuvant in an oil-in-water emulsion (SE)” PMID 26571311 ↗ Nov 20154“45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion” NCT01147068 ↗ “G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE).” NCT03742804 ↗ “Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).” NCT01864876 ↗ |
| Known as | GLA | “G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE).” NCT03742804 ↗ |
| Route | Subcutaneous | “5 mcg GLA-AF given as one subcutaneous injection.” NCT01864876 ↗ |